Applied DNA Sciences has closed the loop on traceability for Egyptian Pima using DNA-based genotyping for cotton authentication. The solution closes the loop for the cotton industry that has been under a cloud of controversy surrounding evidence of cotton products labeled as Egyptian cotton versus those which are actually grown in Egypt. There is no substitute for DNA analysis when it comes to cotton traceability and transparency because of its ability to do what other technologies cannot do, which is to forensically authenticate the fiber through to yarn and finished goods.

Forensic Authentication of Cotton in Fiber, Yarn, Fabric and Finished Goods

STONY BROOK, N.Y., May 30, 2019. Applied DNA Sciences, Inc. (“Applied DNA,” “the Company,” NASDAQ: APDN), today announced that it has closed the loop on traceability for Egyptian Pima using DNA-based genotyping assays for cotton authentication. These assays have been used to verify fiber and will be extended to yarn, fabric and finished goods in an ongoing validation program. The Egyptian Pima developments join and expand a series of US Pima cotton assays performed within Applied DNA testing services and are based on work conducted over the past 3 years related to the validation of a known library of cotton cultivar standards.

“This solution closes the loop for the cotton industry that has been under a cloud of controversy surrounding evidence of cotton products labeled as Egyptian cotton versus those which are actually grown in Egypt. There is no substitute for DNA analysis when it comes to cotton traceability and transparency because of its ability to do what other technologies cannot do, which is to forensically authenticate the fiber through to yarn and finished goods,” stated Dr. Michael Hogan, vice president, Life Sciences, Applied DNA. When paired with SigNature^® T  DNA tagging, testing and tracking of cotton at the gin, it is expected that these new cotton assays, along with other methods of fiber quantitation in the development pipeline at Applied DNA, can now broaden our multiple-parameter analysis to verify the type of cotton, the cotton’s origin, and the blending of the cotton fiber (both valid and surreptitious) during the journey from the ginned fiber to a finished textile product.

In August 2016, the controversy of home bedding and other products labeled 100% Egyptian Cotton hit an all-time high when a number of US retailers recalled many products from retail shelves due to label claim violations, and consumers were informed that products did not meet the standard or label requirement. Three years later, Applied DNA will begin to validate and market test products that are labeled to contain 100% Egyptian Pima in addition to these services for US Pima. Recently, a federal judge ruled that several “Big Box” stores must face lawsuits claiming they sold linens falsely labeled “Egyptian Cotton.” Applied DNA believes its new Egyptian genotyping assays could assist in protecting against such an imbroglio if the retailers used this technology in their supply chains to verify their goods.

“Our cotton authentication platform of SigNature T and genotyping can provide a means for quality control and compliance in supply chains. Many products use cotton grown in the US and Egypt, and we believe that our system can provide a useful tool to enable brands and manufacturers to verify their products at any stage of the supply chain, that is more exact than other methods claiming to do the same without the same degree of precision,” stated Dr. James Hayward, president and CEO of Applied DNA.

“The Himatsingka Group remains committed to bringing cotton traceability for all major varietals of cotton including Egyptian cotton, while maintaining the highest standards of traceability solutions and quality control mechanisms. We applaud Applied DNA for advancing the solutions for the cotton industry as we believe that DNA science is the new standard for purity and authenticity,” stated Shrikant Himatsingka, CEO of The Himatsingka Group.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, ability to maintain its NASDAQ listing and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
media contact: Meryl Rader, 781-639-4924, meryl@cgprpublicrelations.com
program contact: MeiLin Wan, 631-240-8849, meilin.wan@adnas.com

Shipments for Follow-on Order Under Existing Supply Agreement Will Commence This Quarter

STONY BROOK, NY. May 21, 2019 – LineaRx, a wholly-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN), announced that it is in process of designing new, custom amplicons for an existing customer in the in vitro diagnostics market. The diagnostic assay is expected to be available and qualified in 2020, potentially resulting in increasing revenue from an existing supply agreement.

The company currently receives annual orders for large-scale DNA from this customer under a 5-year supply agreement executed in 2017.  The second annual purchase under the supply agreement was received earlier this year, and shipments will commence this quarter and continue for the following 3 quarters.  This purchase order yields revenue in excess of $500,000.We believe linear DNA is ideal for diagnostic applications in that modifications to the target amplicon made through the PCR process are faster, more efficient and less costly than traditional chemical derivatization. The molecular diagnostics market is projected to reach $11.54 billion by 2023 from $7.10 billion in 2017 at a CAGR of 8.4% (MarketsandMarkets.com; May 2018).

“The request for LineaRx to provide a new linear amplicon for a future diagnostic assay is a testament to the merits of linear DNA as well as our large-scale production capabilities,” said Brian Viscount, Director of Product Management at LineaRx.  “If the amplicon is qualified by our customer, we expect recurring shipments under our supply agreement to increase in calendar 2020.”

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, ability to maintain its NASDAQ listing and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
program contact:  Brian Viscount, 631-240-8877, brian.viscount@adnas.com 

FRANKFURT – Industrial sewing thread manufacturer American & Efird (A&E) has partnered with molecular technologies specialist Applied DNA to develop its new Integrity branded threads; a product the companies are debuting at this year’s Texprocess event in Frankfurt, Germany. Chris Remington spoke with A&E’s vice president global retail solutions, Robert Hallett, and Applied DNA managing director for the EMEA region, Tony Benson to learn more.

Company to Hold Conference Call and Webcast Today, Thursday, May 9, 2019 at 4:30 PM EST

STONY BROOK, N.Y. May 9, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), announced consolidated financial results for the fiscal 2019 second quarter ended March 31, 2019.

“We successfully closed on a definitive agreement with TheraCann that contained the largest payment transaction in company history. This new revenue stream beachhead from legal cannabis sits beside the considerable progress we have made in driving adoption of our DNA technology platform and its commercialization across global textile industries,” stated Dr. James A. Hayward, president and CEO of Applied DNA. “Our exclusive cannabis licensing and cooperation agreement with TheraCann secures $5 million in up-front payments by August 15, 2019 (of which $1 million has already been received) and includes annual minimum commitments that scale over time to $20 million in order to maintain the exclusive license. Powered by our CertainT® platform, TheraCann’s ETCH biotrace™ system can offer the global legal cannabis and hemp industries what we believe is an unparalleled ability to ensure true authentication and provenance verification.”

“Growing worldwide demand for legalized cannabis is driving the creation of global supply chains that need to be secured and validated from inception through consumption. TheraCann’s market position, together with our proven molecular tags and application and authentication systems, is yielding a pipeline of opportunities that spans interest from numerous countries wanting to protect their licensed cannabis supply chain to commercial trials for international export opportunities.”

Continued Dr. Hayward, “Within our textile practice, our initiatives to further penetrate the very large synthetic fiber market are beginning to bear fruit. Initial volumes of goods tagged under our CertainT licensing platform are now appearing at retail via Amazon.com and on the store shelves of a big box retailer in North America. We are also executing on our strategy to engage key participants along multiple points in the global textile value chain to more broadly drive adoption of our platform. To that end, we are today involved in active pilot projects with fiber manufacturers that cumulatively represent approximately 50% of the annual global market for viscose. In cotton, after the close of the quarter, we announced our entry into the Egyptian cotton market to demonstrate the same level of authenticity and accountability to manufacturers of luxury Egyptian cotton products as we have to the U.S. cotton industry.

“Cannabis, textiles and our wholly-owned subsidiary, LineaRx are expected to drive our top-line performance for the balance of fiscal 2019 while we also progress nascent opportunities in other industries, including pharmaceuticals, ” concluded Dr. Hayward. “We believe market trends are becoming tailwinds for us: sustainability in manufacturing is becoming increasingly relevant to today’s consumer, and manufacturers are seeking to elevate brands and products by establishing the transparency and truth that consumers desire. Our DNA technology platform can be the basis for the trust that both sides seek.”

Fiscal Second Quarter 2019 Financial Results:

• Revenues decreased 25% for the second quarter of fiscal 2019 to $778 thousand, compared with $1.0 million reported in the second quarter of fiscal 2018, and decreased 12% from the $884 thousand reported in the first fiscal quarter ended December 31, 2018. The year-over-year decrease in revenues was due primarily to a decrease in product revenues of $315 thousand from our biopharmaceutical and consumer asset marking verticals. The quarter-over-quarter decrease in revenues reflects the fulfillment of a cotton order during the first quarter of fiscal 2019.
• Effective October 1, 2018, the Company was required to adopt Accounting Standards Update (ASU; the “Update”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), utilizing the modified retrospective method. Had the Company not adopted the Update, the Company would have recognized additional revenue of approximately $440 thousand and $830 thousand during the second quarter and first six months of fiscal 2019, respectively. These amounts were primarily comprised of the recognition of $383 thousand and $766 thousand during the three and six months periods ended March 31, 2019, respectively, under a $1.15 million cotton order shipped in June 2018, with extended payment terms. The total cumulative impact of the Update that was recorded to opening retained earnings in fiscal 2019 was approximately $494 thousand. See Cumulative Effect Adjustment and the Impact on Current Period Financial Statements of Adopting Topic 606 attached.
• Total operating expenses increased to $3.3 million for the second fiscal quarter of 2019, compared with $2.8 million in the prior fiscal year’s second quarter. This increase is primarily attributable to an increase in stockbased compensation expense.
• Net loss for the quarter ended March 31, 2019 was $2.7 million, or $0.08 per share, compared with a net loss of $2.1 million, or $0.07 per share, for the quarter ended March 31, 2018 and a net loss of $3.2 million, or $0.11 per share for the quarter ended December 31, 2018.
• Excluding non-cash expenses, Adjusted EBITDA was negative $2.3 million for the quarters ended March 31, 2019 and 2018. See below for information regarding non-GAAP measures.

Six-Month Financial Highlights:

• Revenues for the first six months of fiscal 2019 totaled $1.66 million, a decrease of 2% from $1.69 million from the same period in the prior fiscal year. The decrease in revenues was due to a decrease in product revenue of $343 thousand, or 41%, offset by an increase in service revenues of $315 thousand, or 37%.
• Operating expenses for the six months ended March 31, 2019 increased by $902 thousand or 14% for the same period last fiscal year. The increase is primarily attributable to an increase in stock-based compensation, offset to a lesser extent by decreases in R&D and depreciation and amortization expenses.
• Net loss for the six months ended March 31, 2019 was $5.9 million or $0.16 per share, compared with a net loss of $5.3 million or $0.18 per share for the six months ended March 31, 2018.
• Excluding non-cash expenses and interest, Adjusted EBITDA for the six months ended March 31, 2019 was a negative $4.9 million as compared to a negative $5.1 million for the same period in the prior fiscal year. See below for information regarding non-GAAP measures.

Select Recent Operational Highlights:

• On May 7th, the Company and American & Effird (“A&E”) announced that A&E will be previewing its new line of advanced molecular-tagged identification threads, branded “integrity”, later this month. A&E will publicly display this latest breakthrough at the upcoming Texprocess show in Frankfurt Germany.
• On April 29, 2019, Applied DNA’s wholly-owned subsidiary, LineaRx announced that it has improved expression levels and survival rates of linear DNA constructs delivered to human T cells without viruses or plasmids. In collaboration with Avectas, a cell engineering technology business enabling the manufacture of cell therapies, LineaRx has achieved a greater than four-fold increase in cell survival, and a more than 50% increase in linear gene expression of a model amplicon. Results were presented by Avectas two weeks ago at the Cell & Gene Meeting on the Mediterranean, attended by more than 50 companies.
• On April 22, 2019, the Company and GHCL announced the launch of “REKOOP” on Amazon.com. REKOOP is verified by the Company’s CertainT platform. The “REKOOP” range of bedding products is meant for the ecologically conscious consumer who is making purchase decisions to support the environment and is supportive of initiatives that help reduce the carbon footprint.
• On April 11, 2019, Applied DNA announced the signing of a non-binding MOU with Netherlands-based Stahl. Under the terms of the MOU, the parties will continue the evaluation of molecular tagging of process chemicals and coatings utilizing Stahl’s product offerings as a point of entry into supply chains for the Company’s molecular tags. Stahl will provide technical expertise to the company relating to the process chemicals used in leather manufacturing.
• On April 8, 2019, the Company’ announced that its wholly owned subsidiary, LineaRx, achieved what it believes to be a biotech industry first with Anti-CD19 expression in human CAR T cells via proprietary nonviral, plasmid-free platform.
• On April 2, 2019, Loftex, a leading manufacturer of high-quality towels, announced that the first retail introduction of their bath towels including recycled PET (rPET) source-verified by Applied DNA’sCertainT® platform are now available at US retail this month. Loftex introduced the eco-friendly towel, partially comprised of rPET materials as part of their commitment to sustainability both in their factory and in their products.
• On March 29, 2019, the Company signed an exclusive cannabis licensing and cooperation agreement with Theracann International. As part of the agreement, Applied DNA is to receive staged payments totaling $5 million by August 15, 2019. The Company announced that the first payment of $1 million was received during April 2019. The agreement also calls for annual payment minimums that scale from $7 million in year three to $20 million in year fifteen to maintain license exclusivity.
• On March 1, 2019, Applied DNA announced that its wholly owned subsidiary, LineaRx and Takis/Evvivax are progressing linear DNA for use as a cancer vaccine. LineaRx shipped TK7 and ConTRT amplicons to Takis/Evvivax in early March as part of the companies’ Joint Development Agreement entered into during September 2018.

Fiscal Second Quarter 2019 Conference Call Information
The Company will hold a conference call and webcast to discuss its fiscal second quarter-end 2019 results on Thursday, May 9, 2019 at 4:30 PM ET. To participate on the conference call, please follow the instructions below. While every attempt will be made to answer investors’ questions on the Q&A portion of the call, due to the large number of expected participants, not all questions may be answered.

To Participate:

• Participant Toll Free:1-844-887-9402
• Participant Toll: 1-412-317-6798
• Please ask to be joined to the Applied DNA Sciences call

Live webcast: https://services.choruscall.com/links/apdn190509.html

Replay (available 1 hour following the conclusion of the live call through May 16, 2019):

• Participant Toll Free: 1-877-344-7529
• Participant Toll: 1-412-317-0088
• Participant Passcode: 10130964
• Webcast replay: https://services.choruscall.com/links/apdn190509.html

For those investors unable to attend the live call, a copy of the presentation is expected to be posted by end of business on May 10, 2019 and available under the ‘Events and Presentations’ section of the company’s Investor Relations web site: https://adnasprod.wpengine.com/molecular-based-security/investors/

Information about Non-GAAP Financial Measures
As used herein, “GAAP” refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company’s historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP.We use this non-GAAP financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

“EBITDA”- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

“Adjusted EBITDA”- is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, shifting enforcement priorities of US federal laws relating to cannabis, ability to maintain its NASDAQ listing and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, 212-838-3777, LHA Investor Relations, shurry@lhai.com
Media contact: Susan Forman, Dian Griesel Int’l., 212-825-3210, sforman@dgicomm.com

APPLIED DNA SCIENCES, INC. CONSOLIDATED BALANCE SHEETS

	March 31, 2019 (unaudited)	September 30, 2018
ASSETS: Current assets:
Cash and cash equivalents	$1,541,141	$1,659,564
Accounts receivable, net	316,204	1,485,938
Inventories	314,675	221,369
Prepaid expenses and other current assets	591,069	635,174
Total current assets	2,763,089	4,002,045
Property and equipment, net	315,751	419,774
Other assets:
Deposits	62,371	62,325
Goodwill	285,386	285,386
Intangible assets, net	799,487	864,203
Total Assets	$4,226,084	$5,633,733
LIABILITIES AND STOCKHOLDERS’ EQUITY: Current liabilities:
Accounts payable and accrued liabilities	$1,014,291	$965,167
Deferred revenue	1,205,469	1,856,693
Total current liabilities	2,219,760	2,821,860
Long-term accrued liabilities	546,114	470,739
Secured convertible notes payable	2,194,568	1,586,631
Total Liabilities	4,960,442	4,879,230
Commitments and contingencies
Stockholders’ (Deficit) Equity Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of Mar 31, 2019 and Sept 30, 2018	–	–
Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of Mar 31, 2019 and Sept 30, 2018	–	–
Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of Mar 31, 2019 and Sept 30, 2018	–	–
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 37,735,157 and 30,112,057 shares issued and outstanding as of Mar 31, 2019 and Sept 30, 2018, respectively	37,735	30,112
Additional paid in capital	253,021,844	249,090,474
Accumulated deficit	(253,793,937)	(248,366,083)
Total stockholders’ (deficit) equity	(734,358)	754,503
Total Liabilities and Stockholders’ (Deficit) Equity	$4,226,084	$5,633,733

APPLIED DNA SCIENCES, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

	Three Months Ended March 31,		Six Months Ended March 31,
	2019	2018	2019	2018
Revenues: Product revenues	$171,261	$486,341	$493,137	$836,474
Service revenues	607,207	557,605	1,169,654	855,149
Total revenues	778,468	1,043,946	1,662,791	1,691,623
Cost of revenues	133,141	372,153	286,626	703,593
Operating Expenses:
Selling, general and administrative	2,528,914	1,996,604	5,611,295	4,589,759
Research and development	651,377	669,813	1,360,941	1,409,880
Depreciation and amortization	97,673	145,280	232,724	302,928
Total operating expenses	3,277,964	2,811,697	7,204,960	6,302,567
LOSS FROM OPERATIONS	(232,632,637)	(2,139,904)	(5,828,795)	(5,314,537)
Other income (expense):
Interest (expense) income, net	(37,417)	–	(69,028)	–
Other expense	(16,703)	(6,305)	(23,254)	(15,385)
Loss before provision for income taxes	(2,686,757)	(2,146,209)	(5,921,077)	(5,329,922)
Provision for income taxes	–	–	–	–
NET LOSS	$(2,686,757)	$(2,146,757)	$(5,921,077)	$(5,329,922)
Net loss per share-basic and diluted	$(0.08)	$(0.07)	$(0.16)	$(0.18)
Weighted average shares outstanding – Basic and diluted	33,399,597	30,112,057	36,384,939	28,879,804

APPLIED DNA SCIENCES, INC. CALCULATION AND RECONCILIATION OF ADJUSTED EBITDA (unaudited)

	Three months ended March 31,		Six months ended March 31,
	2019	2018	2019	2018
Net loss	$(2,686,757)	$(2,146,209)	$(5,921,077)	$(5,329,922)
Interest expense (income), net	37,417	–	69,028	–
Depreciation and amortization	97,673	145,280	232,724	302,928
Stock based compensation expense	267,094	(285,045)	757,338	(53,932)
Bad debt expense	–	17,117	(8,633)	17,117
Total non-cash items	402,184	(122,648)	1,050,457	266,113
Consolidated Adjusted EBIDTA (loss)	$(2,284,573)	$(2,268,857)	$(4,870,620)	$(5,063,809)

APPLIED DNA SCIENCES, INC. CUMULATIVE EFFECT ADJUSTMENT AND THE IMPACT ON CURRENT PERIOD FINANCIAL STATEMENTS OF ADOPTING TOPIC 606 (unaudited)

	Three months ended December 31, 2018 (unaudited)
	Prior U.S. GAAP	Topic 606 impact	As reported
Statement of operations
Revenues
Product	$554,357	$(383,096)	$171,261
Service	663,816	(56,609)	607,207
Total revenues	$1,218,173	$(439,705)	$778,468
Cost of revenues	$136,474	$(3,333)	$133,141
Loss from operations	$(2,196,265)	$(436,372)	$(2,632,637)
	Six months ended December 31, 2018 (unaudited)
	Prior U.S. GAAP	Topic 606 impact	As reported
Statement of operations
Revenues
Product	$1,259,329	$(766,192)	$493,137
Service	1,233,891	(64,237)	1,169,654
Total revenues	$2,493,220	(830,429)	$1,662,791
Cost of revenues	$293,293	$(6,667)	$286,626
Loss from operations	$(5,005,032)	$(823,763)	$(5,828,795)
Assets:
Prepaid and other current assets	$597,736	$(6,667)	$ 591,069
Liabilities and stockholders’ equity
Deferred revenue	$875,232	$330,237	$1,205,469
Accumulated deficit	$(253,463,700)	$(330,237)	$ (253,793,937)

STONY BROOK, NY. May 7, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today that American & Efird (A&E), a portfolio company of Elevate Textiles and the world’s foremost manufacturer and distributor of industrial and consumer sewing thread, embroidery thread and technical textiles, has announced it will be previewing its new line of advanced identification threads, branded “Integrity” later this month. A&E will publicly display this latest breakthrough at the upcoming Texprocess trade show in Frankfurt Germany.

“One of the big challenges brands face today centers around authenticity. Loss of revenue, reputation, and brand trust are some of the potential outcomes of counterfeit products,” said A&E President, Chris Alt. “We are looking forward to previewing our new ‘Integrity’ line at the upcoming Texprocess show in Frankfurt.”

Well known for its leadership role in innovation, product quality, and sustainability, A&E supports many of the world’s top industrial and consumer brands with thread products that require strict quality and performance. A&E’s new “Integrity” thread line provides a tool which adds advanced identification for greater visibility and transparency into their product creation process.

“Our collaboration with A&E to adopt the CertainT^® platform globally is a key breakthrough for brands, which have not had the benefit of forensic systems to help them resolve counterfeit and diversion in their supply chains. We look forward to providing our full spectrum molecular brand assurance that also includes forensic expert witness and authentication services to support A&E and its customers in apparel, footwear, automotive, military and beyond,” stated Dr. James Hayward, president and CEO of Applied DNA.To learn more on A&E’s “Integrity” molecular-tagged thread products, please visit amefird.com.

Media: Materials and images are available via download.

About American & Efird
A&E, a portfolio company of Elevate Textiles, is the foremost manufacturer and distributor of premium quality industrial and consumer sewing thread, embroidery thread and technical textiles. Producers of apparel, automotive components, home furnishings, medical supplies, footwear and a diverse range of industrial products rely on A&E industrial sewing thread to manufacture their products. Customers select A&E as the preferred choice for industrial sewing thread, embroidery thread and technical textiles because of A&E’s dedication to providing its customers with the finest products and services, at the highest quality, delivered globally. Through its global network, A&E’s products are manufactured in 22 countries, distributed in 50 countries and sold in over 100 countries. In addition to A&E’s steadfast commitment to superior quality and customer service, A&E is a recognized industry leader in environmental sustainability and corporate social responsibility and operates its global facilities with the utmost regard for the safety and health of its associates employed worldwide. A&E owns or operates 28 manufacturing facilities and employs over 10,000 associates around the world directly or in partnership with joint venture partners.

For more information, please visit amefird.com.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on February 7, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
media contact: Meryl Rader, 781-639-4924, meryl@cgprpublicrelations.com
program contacts:  Jacob Blackburn, 704-951-2645, jacob.blackburn@amerfird.com
MeiLin Wan, 631-240-8849, meilin.wan@adnas.com
web: www.adnas.com, www.amefird.com
twitter: @APDN, @AmericanEfird

Applied DNA Sciences, a leader in PCR-based manufacturing for product authenticity and traceability solutions, has received an order for the implementation of its SigNature T cotton traceability system in Egypt to indelibly mark two varietals of high-value Egyptian Cotton, widely acknowledged to be among the finest in the world.

The molecular tag and delivery system have been shipped and cotton tagging is expected to commence within the month. The system, already installed in eight cotton gins worldwide, includes the use of unique SigNature T molecular tags, internet-based data collection linking evidence of tagging process quality to each bale ID, and bar code scanning of tagged packaged bales for inventory management and tracking.

SigNature^® T Traceability System to be Installed in Egypt to Tag Two Cotton Varietals

STONY BROOK, N.Y., May 2, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based manufacturing for product authenticity and traceability solutions, announced today it received an order for the implementation of its SigNature^® T cotton traceability system in Egypt to indelibly mark two varietals of high-value Egyptian cotton, widely acknowledged to be among the finest in the world. The molecular tag and delivery system have been shipped and cotton tagging is expected to commence within the month. The system, already installed in eight cotton gins worldwide, includes the use of unique SigNature T molecular tags, internet-based data collection linking evidence of tagging process quality to each bale ID, and bar code scanning of tagged packaged bales for inventory management and tracking. The cotton fiber will be managed with strict protocols throughout the supply chain to ensure purity and traceability.

“With receipt of this order for Egyptian cotton supply chain tagging and testing, we are moving to replicate our success in securing U.S. cotton through its supply chain. Given the uncertainty surrounding the provenance of Egyptian cotton in the marketplace and growing calls for increased transparency and traceability by consumers, brands and industry advocates, the implementation of our SigNature T cotton traceability system endeavors to ensure that the value of Egyptian cotton can be substantiated throughout its supply chain,” said Dr. James A. Hayward, president and CEO of Applied DNA.

According to the Mundi Report, Egypt produced approximately 240 million pounds of cotton in the prior 2018 growing season, just below total U.S. Pima output.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, shifting enforcement priorities of US federal laws relating to cannabis, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on February 7, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay Hurry, 212-838-3777, shurry@lhai.com
media contact: Meryl Rader, 781-639-4924, meryl@cgprpublicrelations.com
program contacts: MeiLin Wan, 631-240-8849, meilin.wan@adnas.com

STONY BROOK, NY. April 29, 2019 – LineaRx, Inc. (the “Company”) a wholly owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today that it has improved expression levels and survival rates of linear DNA constructs delivered without viruses or plasmids to human T cells. In collaboration with Avectas, a cell engineering technology business enabling the manufacture of cell therapies, LineaRx has achieved a greater than four-fold increase in cell survival, and a more than 50% increase in linear gene expression of a model amplicon. Results were presented by Avectas last week at the Cell & Gene Meeting on the Mediterranean, attended by more than 50 companies.

“We expect to achieve expression levels of LinCART19™ that will permit our analysis of tumor kill rates in vitro and in animal models, allowing us to complete our preclinical evaluation of this promising therapy,” said Dr. James Hayward, president and CEO of Applied DNA. “We can now see that therapeutic doses are well within our planned range of numbers of redirected T cells. In addition to the pursuit of our own therapies, we are being increasingly approached by companies who see the value of linear DNA in gene and redirected cell therapies.”

Dr. Michael Maguire, CEO of Avectas said, “This is an exciting example of how Solupore^® non-viral cell engineering is being used in a next-generation therapeutic product candidate. Through a simpler cell engineering process, Solupore^® technology will improve the efficacy and accessibility of such potentially curative products.”

In October 2018, LineaRx announced an exclusive North American licensing and research services agreement with iCell Gene Therapeutics (“iCell”) for an anti-CD19 CAR T therapy. Leveraging Applied DNA’s expertise in large-scale PCR-based production and chemical modification of DNA, LineaRx will utilize its non-viral, plasmid-free (NVPF) platform to develop and produce expression vectors for CAR T therapies, including its own anti-CD19 CAR T therapy candidate, LinCART19.

As presented at the LineaRx Analyst Day on December 6, 2018, the CAR-T gene construct upon which LinCART19 is based, led to 3 of 3 complete remissions in patients with acute lymphocytic leukemia (ALL) up to 9 months at a very-low-dose in a clinical trial conducted by iCell in China under local regulations. While these promising clinical results provide evidence in the value of the genetic code utilized, the CAR T cells were transfected via a viral vector. LinCART19 will utilize linear DNA transfected by non-viral delivery into T Cells.

The Company recently announced the first anti-CD19 expression in human T cells from a gene construct utilizing linear DNA produced via a scalable PCR manufacturing process. Without the use of viral vectors or plasmids, LineaRx’s NVPF manufacturing platform holds numerous potential advantages over existing viral/plasmid-based CAR T approaches offering the possibility of more efficient, affordable and safer gene therapies for patients.

About Avectas
Avectas is a cell engineering technology business, enabling the manufacture of cell therapies. Avectas’ technology, Solupore^®, delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of primary cell types including T cells for immuno-oncology and gene editing applications. Solupore^® utilizes a membrane disruptive approach to rapidly deliver advanced molecules to cells. It is a simple, rapid and gentle process that yields superior engineered cells. Solupore^® results in improved cell processing times and cell health relative to viral vectors and electroporation, leading to a more cost-effective manufacturing process. Avectas is currently partnering with immuno-oncology and gene editing businesses to deliver their proprietary molecules. Avectas is also seeking therapeutic molecules to in-license as the core of a therapeutic program.

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria. Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on February 7, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
program contact:  Brian Viscount, 631-240-8877, brian.viscount@adnas.com 
web: www.adnas.com, www.linearxdna.com
twitter: @APDN, @LineaRxDNA